NOISEReport
Coverage history

Assembled by NOISE.

Report / Tech

Published by NOISE

Amgen combo cuts death risk by 58% in aggressive lung cancer

From Morning NOISE.

Amgen presented full late-stage trial results at the European Society for Medical Oncology Congress showing that adding its immunotherapy Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone, and nearly 80% of combo patients were alive at one year versus 53%. The fast-growing cancer accounts for an estimated 60% to 70% of roughly 31,000 new U.S. small cell lung cancer cases each year, and the results could position Imdelltra as an earlier treatment option.

Saved versions

These dates record changes to NOISE’s copy. They are not event dates.

  1. Retained copyCurrentIn saved edition